Nov
23
2021
Upcoming webinar

Magnetic selection for consistent cellular starting material in autologous cell therapy manufacture

Tuesday November 23rd 2021 8am PST / 11am EST / 4pm GMT / 5pm CET

An efficient cell selection method is crucial to delivering a consistent autologous therapy product when the starting material received from severely ill patients is highly variable. While a variety of technologies are being adopted in the industry, there are very few GMP options, and many lack the flexibility for multiple passes, and flexibility in reagent selection. In addition, the currently available technologies are often applied in combination with manufacturing platforms that are manual, semi-automated and lacking commercial viability.

During this webinar, our experts will share insights on obtaining highly purified cells using magnetically active cell selection in a flexible, closed manufacturing system. In addition, we will learn about transitioning manual cell therapy production to automated processes that are scalable to meet clinical and commercial demands.

  • Background, and the current status, of the Malaghan Institute’s CD19 cell therapy in a Phase I clinical trial
  • Translation of Malaghan's open, manual manufacturing process into a fully automated workflow from sample loading, cell selection to harvest
  • Magnetic selection in the Cocoon® Platform and results

Kenneth Olsen, PhD

Senior R&D Scientist, Personalized Medicine Business Unit, Lonza

Dr. Kenneth Olsen received his BSc in Biomedical Sciences, and his Masters in Biology and Vision Science from the University of Waterloo. He received his PhD from the Institute of Medical Sciences at the University of Toronto where he developed a novel device for generating biomechanical compression as a cellular model for glaucoma. After a postdoctoral research associate position at the University of Utah, and a Postdoctoral Fellow at the Canadian Centre for Alternative to Animal Methods at the University of Windsor, Dr. Olsen joined the Lonza Personalized Medicine R&D team as a Senior Scientist in July 2021.

Rachel Perret, PhD

Team Leader, CAR T-cell Research Program, Malaghan Institute of Medical Research

Dr. Rachel Perret is a Senior Cancer Research Fellow and Team Leader of the CAR T-cell Research Programme at New Zealand’s Malaghan Institute of Medical Research. She studied Microbiology at the University of Otago, NZ, before undertaking her PhD in Immunology with Professor Franca Ronchese at the Malaghan Institute. Rachel spent several years overseas, first at the Lausanne Branch of the Ludwig Institute for Cancer Research, and then at the Fred Hutchinson Cancer Research Center, and returned to the Malaghan Institute in January 2020. Her research focus lies in investigating chimeric antigen receptor (CAR) T-cell signalling and function, in order to design even better, safer, and more broadly applicable CAR T-cell therapies for cancer

34
Days
11
Hrs
44
Min

SPEAKERS

Kenneth Olsen, PhD
Senior R&D Scientist, Personalized Medicine Business Unit, Lonza
Kenneth Olsen, PhD
Senior R&D Scientist, Personalized Medicine Business Unit, Lonza
Rachel Perret, PhD
Team Leader, CAR T-cell Research Program, Malaghan Institute of Medical Research
Rachel Perret, PhD
Team Leader, CAR T-cell Research Program, Malaghan Institute of Medical Research
Dr. Rachel Perret is a Senior Cancer Research Fellow and Team Leader of the CAR T-cell Research Programme at New Zealand’s Malaghan Institute of Medical Research. She studied Microbiology at the University of Otago, NZ, before undertaking her PhD in Immunology with Professor Franca Ronchese at the Malaghan Institute. Rachel spent several years overseas, first at the Lausanne Branch of the Ludwig Institute for Cancer Research, and then at the Fred Hutchinson Cancer Research Center, and returned to the Malaghan Institute in January 2020. Her research focus lies in investigating chimeric antigen receptor (CAR) T-cell signalling and function, in order to design even better, safer, and more broadly applicable CAR T-cell therapies for cancer